CTI BioPharma Corp. (DE) Common Stock
CTIC
CTIC was delisted on the 23rd of June, 2023.
67 hedge funds and large institutions have $142M invested in CTI BioPharma Corp. (DE) Common Stock in 2018 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 21 increasing their positions, 3 reducing their positions, and 10 closing their positions.
652% more call options, than puts
Call options by funds: $451K | Put options by funds: $60K
600% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 3
168% more capital invested
Capital invested by funds: $52.7M → $142M (+$88.8M)
140% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 10
26% more funds holding
Funds holding: 53 → 67 (+14)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$13.2M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$12.2M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$11.6M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$5.93M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$5.86M |
| 2 |
Jane Street
New York
|
-$472K |
| 3 |
TA
Tiedemann Advisors
New York
|
-$196K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$176K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$170K |
CTIC Hedge Fund Activity: Q1 2018 in Review
67 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q1 2018, worth a combined $142M — up 168% from $52.7M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new CTIC positions and 10 closed out — a net gain of 14 holders — while 21 added to existing stakes and 3 trimmed.
The largest buyer was NEA Management Company, opening a new position worth an estimated $13.2M. The largest seller was BVF Inc, cutting an estimated $5.86M.
- 67 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q1 2018, up from 53 in Q4 2017.
- Funds reported $142M of CTI BioPharma Corp. (DE) Common Stock stock for Q1 2018, up 168% quarter-over-quarter.
- 24 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q1 2018 and 10 closed out, a net change of +14 holders.
- The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q1 2018 was NEA Management Company, an estimated $13.2M added.
- The largest CTI BioPharma Corp. (DE) Common Stock seller in Q1 2018 was BVF Inc, an estimated $5.86M sold.
Based on aggregated 13F filings for Q1 2018.